Search for: "Novartis Pharma AG"
Results 1 - 20
of 124
Sort by Relevance
|
Sort by Date
5 Sep 2023, 2:39 am
Cir. 2007) and Novartis AG v. [read post]
5 Apr 2023, 5:18 am
This then came before Arnold LJ in the Teva UK Limited and anor v Novartis AG [2022] EWCA Civ 1617 who agreed that no Arrow declaration should be made. [read post]
22 Sep 2022, 9:54 am
Most recently, Novartis AG plans to appeal a case to the U.S. [read post]
18 Jul 2022, 2:11 pm
Novartis Pharma AG According to a recent case in the U.S. [read post]
7 Mar 2022, 12:44 am
The machinations on the application of Article 3 to combination SPCs is just yet another example of the hazy ground that can open up between these two imperatives.Further reading28 June 2019: SPCs based on a second marketing authorisation - the fight continues (Novartis C-354/19)13 September 2019: Article 3(a) just keeps on giving: AG Opinion in SPC referrals C-650/17 and C-114/1817 May 2021: Does the Irish Court of Appeal in Merck v Clonmel part ways from the… [read post]
21 Feb 2022, 4:27 am
The case before the Swedish courts Novartis AG (“Novartis”) filed a lawsuit against Abacus Medicine A/S (“Abacus”), claiming that Abacus infringed its trademarks by replacing the original package of certain parallel imported medicinal products. [read post]
24 Jan 2022, 5:03 am
So what happened in Novartis Pharma AG and others ./. [read post]
13 Dec 2021, 12:49 am
The meaning of Article 3(c) with respect to combination products was referred to the CJEU in Novartis (C-354/19) (IPKat). [read post]
3 Nov 2021, 1:05 pm
The court said that the generic companies’ manufacturing or selling of these tablets may amount to infringement of a patent owned by major pharmaceutical company Novartis AG. [read post]
26 Apr 2021, 7:42 am
Novartis AG is working with Pfizer Inc. to fill vials quicker and to develop the mRNA needed for a new vaccine candidate produced by CureVA NV. [read post]
7 Jan 2021, 1:32 pm
To start, Beovu was approved by the FDA on October 7, 2019, to treat wet age-related macular degeneration. [read post]
22 Sep 2020, 2:15 pm
" Returning to the recent announcement about that Phase 3 study, we get the following from this September 14, 2020 Fierce Pharma article, "Novartis, stressing Beovu safety, matches Eylea in head-to-head diabetic macular edema trial": Normally, late-stage trial announcements center on a drug’s efficacy, but Novartis singled out Beovu’s safety performance in its statement. [read post]
4 Mar 2020, 1:56 pm
Most of the cases have started after patients’ first or second injection of the wet age-related macular degeneration (AMD) drug, Novartis said. [read post]
7 Nov 2019, 8:10 pm
., 37%; Novo Nordisk AS, 17%; Novartis AG, 14%; and Merck KGa, 13%; Hoffmann-La Roche, 12.7%). [read post]
30 Apr 2019, 7:22 am
Final panellist Jürgen Dressel (ex- Novartis Pharma AG) explained that, going back to basics, the SPC is meant to be a reward for R&D and there should be legal certainty and a harmonised situation for the international market. [read post]
30 Apr 2019, 5:29 am
Jürgen Dressel (ex- Novartis Pharma AG) further commented that of course there is the further issue in Germany that invalidity proceedings cannot even be commenced whilst EPO opposition proceeding are ongoing. [read post]
28 Apr 2019, 8:20 am
In the Rituximab case (District Court of Munich, May 2017), the court said that the generic case law stipulating that the balance of interests in principle favors the originator cannot be applied to biosimilar situations and that a full assessment of the specific circumstances is required in each case.From the audience Jürgen Dressel (ex-Novartis Pharma AG, Basel) asked about the uptake of biosimilars and whether costs will decrease the more medicines… [read post]
20 Dec 2018, 10:14 am
In the second decision, Novartis AG v. [read post]
9 Dec 2018, 9:59 pm
Noonan -- In Novartis AG v. [read post]
7 Dec 2018, 12:58 am
Only then did the French Patent Office grant the new SPC to Novartis Pharma AG with decision of 4 June 2018. [read post]
